JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

148.21

+0.39%↑

Home・Akcijų sąrašas・MacroGenics Inc

MacroGenics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.84 0.55

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.81

Max

1.87

Pagrindiniai rodikliai
By Trading Economics
Pajamos	4.8M -36M
Pardavimai	9M 22M
Pelno marža	-162.992
Darbuotojai	341
EBITDA	5.7M -33M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+104.92% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	15M 108M
Ankstesnė atidarymo kaina	1.29
Ankstesnė uždarymo kaina	1.84

Naujienos nuotaikos

By Acuity

50%

145 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

1.47 / 1.64 Palaikymas ir pasipriešinimas

MacroGenics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-24 18:41; UTC

Uždarbis

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

2025-10-24 18:31; UTC

Uždarbis

Correction to Procter & Gamble to Focus on Innovation

2025-10-24 16:25; UTC

Pagrindinės rinkos jėgos

Obook Shares Rise, Company Secures New Money Transmitter Licenses

2025-10-24 21:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-24 21:24; UTC

Rinkos pokalbiai

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

2025-10-24 21:07; UTC

Uždarbis

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

2025-10-24 20:58; UTC

Uždarbis

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

2025-10-24 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-24 20:40; UTC

Uždarbis

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

2025-10-24 20:24; UTC

Uždarbis

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025-10-24 20:23; UTC

Uždarbis

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

2025-10-24 20:13; UTC

Uždarbis

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 20:07; UTC

Rinkos pokalbiai

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

2025-10-24 19:40; UTC

Rinkos pokalbiai

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

2025-10-24 19:35; UTC

Rinkos pokalbiai

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

2025-10-24 19:33; UTC

Uždarbis

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

2025-10-24 19:29; UTC

Rinkos pokalbiai

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

2025-10-24 18:52; UTC

Uždarbis

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025-10-24 18:41; UTC

Uždarbis

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

2025-10-24 18:03; UTC

Uždarbis

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

2025-10-24 18:02; UTC

Uždarbis

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

2025-10-24 18:00; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

2025-10-24 16:57; UTC

Uždarbis

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

2025-10-24 16:54; UTC

Rinkos pokalbiai

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

2025-10-24 16:44; UTC

Rinkos pokalbiai

Uždarbis

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

2025-10-24 16:39; UTC

Rinkos pokalbiai

Uždarbis

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

2025-10-24 16:33; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 16:23; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

2025-10-24 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-10-24 16:07; UTC

Uždarbis

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

MacroGenics Inc Prognozė

Kainos tikslas

By TipRanks

104.92% į viršų

12 mėnesių prognozė

Vidutinis 3.75 USD 104.92%

Aukščiausias 5 USD

Žemiausias 3 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MacroGenics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių MacroGenics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.47 / 1.64Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

145 / 371 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.